Varicella Zoster Virus ORF9 (VZV VP22) (AA 6-28), (AA 76-100) Protein

Produktnummer ABIN935888

Dieses Recombinant Varicella Zoster Virus ORF9-Protein wird in Escherichia coli (E. coli) produziert.

Kurzübersicht für Varicella Zoster Virus ORF9 (VZV VP22) (AA 6-28), (AA 76-100) Protein (ABIN935888)

Target: Varicella Zoster Virus ORF9 (VZV VP22)

Protein-Typ: Recombinant

Spezies: Varicella Zoster Virus (VZV)

Quelle: Escherichia coli (E. coli)

Applikation: Western Blotting (WB), ELISA

Reinheit: > 95 % pure

Produktdetails

Proteineigenschaft: AA 6-28, AA 76-100

Produktmerkmale: Purified recombinant VZV ORF9 protein
Expression System: E.coli

Aufreinigung: Proprietary chromatographic technique

Anwendungsinformationen

Applikationshinweise: Each Investigator should determine their own optimal working dilution for specific applications.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: 25 mM tris-HCl, pH 8.0, with 5 mM EDTA and 50 % glycerol.

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Antigendetails

Target: Varicella Zoster Virus ORF9 (VZV VP22)

Substanzklasse: Viral Protein

Hintergrund: VZV is closely related to the herpes simplex viruses (HSV), sharing much genomehomology. The known envelope glycoproteins (gB, gC, gE, gH, gI, gK, gL) correspond with those in HSV, however there is no equivalent of HSV gD. VZV virons are spherical and 150-200 nm in diameter. Their lipidenvelope encloses the nucleocapsid of 162 capsomeres arranged in a hexagonalform. Its DNAis a single, linear, double-stranded molecule, 125,000 nt long. The virus is very susceptible to disinfectants, notably sodium hypochlorite. Within the body it can be treated by a number of drugs and therapeutic agents including aciclovir, zoster-immune globulin (ZIG), and vidarabine.
Alternative Names: Varicella Zoster Virus ORF9 protein